Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935919 | 0.98 | — | — | |
| SCHEMBL3392861 | 0.78 | CYP1A2 (0.48) | CYP1A2CYP2C19PDPK1MEN1KMT2A | |
| SCHEMBL6938627 | 0.70 | CYP1A2 (0.42) | CYP1A2CYP2C19PDPK1ALDH1A1KDM4E | |
| SCHEMBL6935926 | 0.70 | CYP1A2 (0.42) | CYP1A2CYP2C19PDPK1ALDH1A1KDM4E | |
| SCHEMBL6938040 | 0.70 | CYP1A2 (0.42) | CYP1A2CYP2C19PDPK1ALDH1A1KDM4E | |
| SCHEMBL8404458 | 0.69 | — | — | |
| SCHEMBL1129344 | 0.68 | CYP1A2 (0.41) | CYP1A2CYP2C19PDPK1ALDH1A1MAPT | |
| SCHEMBL6796490 | 0.67 | PDPK1 (0.45) | CYP1A2CYP2C19PDPK1MEN1KMT2A | |
| SCHEMBL12051534 | 0.67 | PDPK1 (0.41) | CYP1A2CYP2C19PDPK1MEN1KMT2A | |
| SCHEMBL4321938 | 0.66 | CYP1A2 (0.39) | CYP1A2CYP2C19MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | CYP1A2 27/4885CYP2C19 3/4885PDPK1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.